Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 103 Cr.
- Current Price ₹ 7.92
- High / Low ₹ 20.1 / 7.75
- Stock P/E
- Book Value ₹ 5.16
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding is low: 26.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | -20% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
General Updates
9 December 2025 - NSE approved listing of 23,270,000 equity shares from warrant conversion; trading effective December 9, 2025.
-
Copy of Newspaper Publication
17 November 2025 - Vaishali Pharma approved and published unaudited Q2/H1 results ended 30 September 2025.
-
Outcome of Board Meeting
14 November 2025 - Board approved Q2/H1 results to Sep 30, 2025; H1 PAT Rs246.38 lakh.
-
Outcome of Board Meeting
14 November 2025 - Unaudited Q2 and H1 results ended 30 Sep 2025 approved; limited review attached.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
14 October 2025 - Reg 74(5) certificate for quarter 01-Jul-2025 to 30-Sep-2025; no rematerialisation requests.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations